Dr. Ke WU Co-Founder, Chief Executive Officer, and Chairman
PhD in Immunology, Dr. Wu is a distinguished professor of Hubei Province, with adjunct appointments at Huazhong University of Science & Technology; Hubei University; and Wuhan Polytechnic University. He is a senior engineer of medical biology, and a recipient of the "3551" Optics Valley Talents.
Dr. Wu has more than 30 years of experience in the biotechnology industry and has successfully developed 7 NMPA biological products. He has received 2 GMP certificates, submitted more than 40 patent applications, and published more than 10 papers. He has led and participated in the development of major national projects, some examples include “National 863 project”; “Shanghai Major Scientific and Technical Breakthroughs”; and “Major New Drug Development”, a special project of the National Science and Technology.
Mr. Jin SHI Co-Founder, Vice President, and Board Director
Mr. Shi is a graduate of Laboratory Sciences from Tongji Medical College, Huazhong University of Science & Technology (formerly Tongji Medical University); an EDP (Executive Development Programs) graduate from the School of Management, Fudan University; a licensed pharmacist; and the member of Hubei Medical Industry Association.
He has 30 years of experience in the biological industry. Prior to joining BravoVax, he worked at the Quality Control Department of Wuhan Institute of Biological Products (1984 – 2004), responsible for the production and quality verification of biologic products. In 2004 he joined Shanghai Zerun Biotechnology Co., Ltd where he held key positions as QA Director, Quality Management Manager, Quality Director, and Qualified Person. Between 2011 and 2013, Mr. Shi served as General Manager of Beijing Huawei BravoBio Co., Ltd. He has strong organizational and managerial skills; in-depth cGMP knowledge; and extensive experience in validations and cGMP certification. He has submitted 10 patents applications pertaining vaccine technology. He was elected for two terms as the principal member of “Strategic Entrepreneurial Team of Hubei Province”.
Mr. Haozhi LIU Co-Founder, Vice President, and Board Director
Mr. Liu is an EDP (Executive Development Programs) graduate from the School of Management, Wuhan University; and a member of the National Supply Chain Branch of Vaccine Industry Association in China.
He has over 20 years of experience in biological industry. Prior to joining BravoVax, he worked at Shanghai Sunway Biotech Co., Ltd, responsible for the development of new products and production processes. He then joined Shanghai Wison Biological Engineering Co., Ltd (later known as Shanghai Zerun Biotechnology Co., Ltd), and held the positions of workshop manager and production manager. He is experienced in cGMP manufacturing of protein-based and bacterial-based vaccines. He has participated in the development of National Class I&II new drugs, including scale-up and industrialization; applied for 11 patents on vaccine technology and 3 utility model patents on equipment. He was elected for two terms as the principal member of the “Strategic Entrepreneurial Team of Hubei Province”.
Mr. Wu Vice President
Mr. Wu is a graduate from Tongji Medical College of Huazhong University of Science & Technology; EMBA of Health Science Center of Peking University.
He has extensive experience in biological products industry and has worked at Hepatitis B Unit, Cell Engineering Unit and Diagnostic Supplies Unit of Wuhan Institute of Biological Products for many years.
Mr. Jianfeng ZHOU Vice President of BravoBio Co., Ltd
Mr. Zhou graduated from Suzhou University, majoring in Industrial Electrical Automation; and received Master of Business Administration from Tongji University. He was the co-founder of Wison Group. He served as the chief auditor of ISO9000 Quality Management System in Det Norske Veritas (DNV), Norway. He is a certified Professional Manager, and National Principal Construction Engineer.
Mr. Zhou has more than 30 years of experience in middle and senior management in state-owned, private, and public companies. He has extensive management experience in strategy development and implementation, manufacturing, quality system, infrastructure and equipment, human resources, and administration, etc.
Dr. Yan-ping YANG Vice President of BravoBio Co., Ltd, R&D (CMC and Late-stage Product Development)
Dr. Yang received PhD in Biochemistry from the University of Missouri, USA. She has >30 years experiences in vaccine research and development with Sanofi Pasteur (Oct 1989 to Mar 2022), with numerous patents, publications, and presentations at the major international conferences.
Prior to joining BravoBio, she was the Head of Bioprocess R&D in North America at Sanofi Pasteur (July 2014 to March 2022), overseeing the efforts of a department of ~100 people in developing vaccine manufacturing processes to support preclinical and clinical studies up to phase III. Her experiences include CMC (Chemistry, Manufacturing and Controls) strategy development and implementation; end-to-end vaccine process development; process scale up, tech transfer and industrialization readiness; patent preparation and regulatory submissions.
Professor Xu Chief Scientist
Professor Xu is currently a professor at the State Key Laboratory of Virology, and School of Life Sciences of Wuhan University; a doctoral tutor at Wuhan University; vice president of Vaccine Research Institute of Wuhan University; chairman of Biosafety Committee of Advanced Biosafety Laboratory of Wuhan University; expert of Biosafety Review of National Pathogenic Microbiology Laboratory; member of Clinical Virology Group, Chinese Medical Association (CMA); member of Chinese Society of Biotechnology (CSBT); member of Hubei Provincial Society of Biotechnology. She also serves as editorial board member of a number of prestigious virology journals, such as Viruses, Frontiers in Cellular and Infection Microbiology, Archives of Virology.
Dr. Michel KLEIN Chairman of Scientific Advisory Board
Dr. Klein received his MD degree from the Faculty of Medicine of Paris and his diploma in Immunology from the Institute Pasteur. He focused on immunology and biotechnology for more than 50 years, including 30 years of experience in bacterial, viral and cancer vaccines development. He has been a full Professor of Immunology at the University of Toronto and held the positions of Vice President Research of Pasteur Mérieux Connaught and of Vice President, Science and Technology, of the Aventis-Pasteur Group, now Sanofi Pasteur.
He is a member of many international professional associations and editorial board member of multiple reputed academic journals. Member of TRANSVAC Steering Committee; Auditor of European Commission Institutional; Member of Academic Advisory Board of the European Vaccine Programme. He is the author of more than 200 scientific publications and several patents in the fields of vaccinology and biotechnology. He is a knight in the French order of the Légion d’Honneur.
Dr. Kelly McKEE Chief Medical Officer
Dr. McKee received his MD degree from the University of Virginia School of Medicine, Charlottesville, Virginia. He has over 30 years of experience in research and development, with specific expertise in vaccines, emerging infectious diseases, biodefense, sexually transmitted infections, and respiratory viral diseases. His progressive clinical research experience began in 1981 at Fort Detrick in Frederick, Md., where he held a variety of leadership positions in virology, immunology, preventive medicine, and clinical research. He subsequently served as state epidemiologist in North Carolina and as senior director of clinical research at DynPort Vaccine Company.
Dr. McKee held multiple leadership roles over the course of his career, including vice president and managing director of public health and government services and vice president for vaccines and public health in the Infectious Diseases and Vaccines Center of Excellence, at Quintiles/QuintilesIMS (now IQVIA). He has also earned multiple board and advisory appointments, certifications, grants, civilian honors, and professional society fellowships. Dr. McKee has authored or co-authored more than 100 peer-reviewed publications and book chapters.
Mr. Liu Project Management Director
Dr. Liu received his PhD in Biochemistry from Fudan University; engaged in postdoctoral research in Johns Hopkins University and Dartmouth College.
He is an associate professor of School of Life Sciences, Hubei University and Project Management Director of BravoVax. He has been selected into a number of talent projects, including Shanghai Oriental Scholars Plan, Shanghai Pujiang Talent Plan, Hubei Hundred Talents Program, Hubei Chutian Scholars Plan, Wuhan 3551 Talent Schema. He has presided over more than ten scientific research projects supported by National Natural Science Foundation of China, Natural Science Foundation of Hubei Province, etc. He has published more than 30 SCI papers, and has been granted many Chinese invention patents and PCT patents. He has good experience in vaccine development, gene editing and therapy.
Mr. Ma Project Management Director
Dr. Ma is a licensed pharmacist, graduated from Wuhan Institute of Biological Products with a master degree.
He has participated in WHO pre-qualification and ICH-related training series organized by PATH; engaged in the R&D and project management of Rotavirus Vaccine, Zika Virus Vaccine and RSV Vaccine programs. He has good experience in biological products and international regulatory registration.
Mr. Feng CFO
Certified public accountant, non practicing lawyer, certified tax agent, chief financial officer of Wuhan bowo Biotechnology Co., Ltd. He has successively served as the audit manager of one of the top ten accounting firms in China, the manager of the Group Investment Department of a listed company, and the chief financial officer and Secretary of a new third board company. He has a complex knowledge system and has rich experience in finance, audit, investment and other fields.
Ms. Zhang Business Development Director
Ms. Zhang is the Business Development Director of BravoVax Co., Ltd, specializing in licensing in/out deals. She graduated from State University of Albany, New York in 2005, with a master degree in molecular biology. Ever since then, she has been doing business development in pharmaceutical companies, especially in the vaccine field. Prior to joining BravoVax, she worked as Business Development Director in Shanghai BravoBio and Business Development Manager in Shanghai Zerun Biotech. And before that, she served as the Client Communication Manager in Shanghai Medicilon which is a preclinical CRO company.
Mr. Kang Chairman of Labor Union
Mr. Kang has been engaged in biological products industry for more than 30 years.
Prior to joining BravoVax, he worked at Wuhan Institute of Biological Products as office director, responsible for research and production of biological products. He played an active role in the research, production and management of anti-human T lymphocyte porcine immunoglobulin and calciferous thromboplastin, and received the GMP certificate for anti-human T lymphocyte porcine immunoglobulin. He participated in the amendment of national regulations for biological products. Later, he joined Hubei Baikang Pharmaceutical Co., Ltd and held the position of Deputy General Manager. During his tenure, he was in charge of new projects development and successfully obtained the clinical trial authorization for one product from SFDA.